Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | FABP6 | P51161 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870891 | 0.80 | FABP6 (0.55) | PLAUABL1FABP6 | |
| SCHEMBL6784014 | 0.80 | NR1H4 (0.55) | NR1H4PLAUROCK2ROCK1CYP4Z1 | |
| Hydrochloric Acid SCHEMBL4682527 | 0.79 | FABP6 (0.54) | PLAUABL1FABP6 | |
| SCHEMBL6784034 | 0.78 | HSP90AA1 (0.64) | NR1H4ROCK2ROCK1CYP4Z1MMP13 | |
| SCHEMBL10022606 | 0.77 | ROCK2 (0.72) | ROCK2ROCK1 | |
| SCHEMBL29032775 | 0.77 | CFD (0.59) | NR1H4PLAUROCK2ROCK1CYP2D6 | |
| SCHEMBL29032785 | 0.77 | CFD (0.53) | PLAUROCK2ROCK1MMP13CYP2D6 | |
| SCHEMBL30452215 | 0.77 | CFD (0.59) | NR1H4PLAUROCK2ROCK1CYP2D6 | |
| SCHEMBL6785734 | 0.76 | ITGB3 (0.47) | PLAUABL1FABP6 | |
| SCHEMBL12109586 | 0.75 | PLAU (0.57) | PLAUCYP2D6EGLN1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | THE PROCTER & GAMBLE COMPANY | 2004-01-08 | — | — | US | disclosed |
| WO-2002016327-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS NEUTROPHIL INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | MPO, SERPINB1, NCF1 | NR1H4 853/4885PLAU 318/4885ROCK2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.